study to assess the absorption, distribution, metabolism and excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM) - ADME
Study identifier:D1020C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open, single-centre, single group, Phase I study to assess the absorption, distribution, metabolism and excretion (ADME) of AZD1656 after oral administration of 14C-labelled AZD1656 to Type II Diabetes Mellitus patients
Medical condition
Type II diabetes mellitus
Phase
Phase 1
Healthy volunteers
No
Study drug
-
Sex
Male
Actual Enrollment
6
Study type
Interventional
Age
35 Years - 65 Years
Date
Study Start Date: 01 Jul 2009
Primary Completion Date: -
Study Completion Date: 01 Sept 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 14C-labelled AZD1656 | Device: AZD1656 Oral single dose |
Contacts
Investigators
Principal Investigator
Klas Malmberg
AstraZeneca R&D Mölndal, SE-431 83 Mölndal, Sweden
